The immune space: A concept and template for rationalizing vaccine development

AIDS Research and Human Retroviruses

Volumn 30, Issue 11, 2014, Pages 1017-1022

  Manrique, Amapola ^a   Adams, Elizabeth ^b   Barouch, Dan H ^c   Fast, Pat ^d   Graham, Barney S ^b   Kim, Jerome H ^e   Kublin, James G ^f   McCluskey, Margaret ^g   Pantaleo, Giuseppe ^h   Robinson, Harriet L ⁱ   Russell, Nina ^j   Snow, William ^a   Johnston, Margaret I ^j  

^a Global HIV Vaccine Enterprise   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Beth Israel Deaconess Medical Center   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ Research and Development   (United States)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ERDOSTEINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG SAFETY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; VIRUS NEUTRALIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASES; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; STANDARDS; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; DRUG DISCOVERY; HUMANS; VACCINATION; VACCINES;

EID: 84931362493     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0040     Document Type: Review

References (20)

1. Blankson JN, Bailey JR, Thayil S, et al.: Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007;81(5):2508-2518.
2. Miura T, Brumme CJ, Brockman MA, et al.: HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 2009;83(7): 3407-3412.
3. Lackner AA, Lederman MM, and Rodriguez B: HIV pathogenesis: The host. Cold Spring Harb Perspect Med [Internet] 2012 [cited 2013 Jul 18];2(9). Available from http://perspectivesinmedicine.cshlp.org/content/2/9/a007005.
4. Swanstrom R and Coffin J: HIV-1 pathogenesis: The virus. Cold Spring Harb Perspect Med [Internet] 2012 [cited 2013 Jul 18];2(12). Available from http://perspectivesinmedicine.cshlp.org/content/2/12/a007443.
5. Evans DT and Silvestri G: Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 2013;8(4):255-261.
6. Coffman RL, Sher A, and Seder RA: Vaccine adjuvants: Putting innate immunity to work. Immunity 2010;33(4): 492-503.
7. Dey AK and Srivastava IK: Novel adjuvants and delivery systems for enhancing immune responses induced by im-munogens. Expert Rev Vaccines 2011;10(2):227-251.
8. Harandi AM, Medaglini D, Shattock RJ, Working Group convened by EUROPRISE: Vaccine adjuvants: A priority for vaccine research. Vaccine 2010;28(12):2363-2366.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23): 2209-2220.
10. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-1286.
11. Jardine J, Julien J-P, Menis S, et al.: Rational HIV im-munogen design to target specific germline B cell receptors. Science 2013;340(6133):711-716.
12. McGuire AT, Hoot S, Dreyer AM, et al.: Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013;210(4):655-663.
13. Klasse PJ, Depetris RS, Pejchal R, et al.: Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 2013;87(17):9873-9885.
14. Haynes BF, Kelsoe G, Harrison SC, and Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30(5):423-433.
15. Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology [Internet]. [cited 2014 Mar 4]. Available from www.fda.gov/downloads/Regulator%20y Information/Guidances/UCM128049.pdf.
16. Lamoreaux L, Roederer M, and Koup R: Intracellular cy-tokine optimization and standard operating procedure. Nat Protoc 2006;1(3):1507-1516.
17. Dubey S, Clair J, Fu T-M, et al.: Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 1999 2007;45(1):20-27.
18. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, and McElrath MJ: Moving to human immunodeficiency virus type 1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187(2):226-242.
19. Horton H, Thomas EP, Stucky JA, et al.: Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007;323(1):39-54.
20. Montefiori DC: Standardized Assessments of Neutralizing Antibodies for HIV/AIDS Vaccine Development [Internet]. [cited 2014 May 15]. Available from www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm.